公开(公告)号：US20170315128A1

公开(公告)日：2017-11-02

申请号：US15375447

申请日：2016-12-12

申请人： MOLECULAR HEALTH GMBH

发明人： David B. Jackson ,  Martin Stein ,  Hartmut Voss ,  Stephan Brock

IPC分类号： G01N33/574 ,  C12Q1/68 ,  G01N33/50 ,  C12N15/113 ,  G01N33/74

CPC分类号： G01N33/57492 ,  C12N15/1138 ,  C12Q1/6886 ,  C12Q2600/106 ,  G01N33/5011 ,  G01N33/5041 ,  G01N33/57415 ,  G01N33/746 ,  G01N2800/52

摘要： There is disclosed a molecular composition(s) of a novel tissue protective erythropoietin (EPO) binding receptor protein complex, termed NEPOR. Presence of NEPOR components on a tumour allows EPO to impinge on the survival of associated cells thereby enhancing tumour progression and negatively effecting patient survival. Presence of NEPOR represents a prognostic biomarker for poorer patient outcome. Thus, methods are provided for stratifying patients having a tumour as suitable (i.e. NEPOR not present) or non-suitable (i.e., NEPOR present) for EPO treatment, comprising: (a) isolating a tissue sample from an individual who is receiving or is a candidate for receiving erythropoietin, (b) determining the level of expression of the NEPOR gene(s) (mRNA) and/or the presence of the NEPOR gene product (protein) from the isolated tissue, and (c) correlating the presence of an NEPOR gene expression product or the presence of NEPOR protein to a physiological response to the treatment with erythropoietin. Furthermore, by disclosing the molecular compositions of NEPOR species, there are disclosed methods for rationally identifying/designing NEPOR modulating therapeutics. Methods also are provided for treating neurological insults such as stroke (via enhancement of NEPOR activity) and cancer (via down-regulation of cyto-protective signaling from NEPOR).